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Abstract 
We have previously developed a new class of inhibitors and chemical probes for 
glycosyltransferases through base-modification of the sugar-nucleotide donor. The key 
feature of these donor analogues is the presence of an additional substituent at the 
nucleobase. To date, the application of this general concept has been limited to UDP-sugars 
and UDP-sugar-dependent glycosyltransferases. Herein, we report for the first time the 
application of our approach to a GDP-mannose-dependent mannosyltransferase. We have 
prepared four GDP-mannose derivatives with an additional substituent at either position 6 or 
8 of the nucleobase. These donor analogues were recognised as donor substrates by the 
mannosyltransferase Kre2p from yeast, albeit with significantly lower turnover rates than the 
natural donor GDP-mannose. The presence of the additional substituent also redirected 
enzyme activity from glycosyl transfer to donor hydrolysis. Taken together, our results 
suggest that modification of the donor nucleobase is, in principle, a viable strategy for probe 
and inhibitor development against GDP-mannose-dependent GTs. 
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Introduction 
Glycosyltransferases (GTs) are a large family of enzymes that catalyse the transfer of a 
sugar from an activated glycosyl donor, frequently a sugar-nucleotide, to a specific acceptor 
[1]. Mannosyltransferases (ManTs) are a subfamily of GTs, which use either 
dolicholphoshate-linked mannose or the sugar-nucleotide GDP-α-D-mannose (GDP-Man) as 
their donor. ManTs play important roles in both eukaryotic and prokaryotic organisms, 
including many human pathogens such as Candida albicans [2], Mycobacterium tuberculosis 
[3], and Trypanosoma brucei [4]. Small molecular inhibitors and probes for ManTs are 
therefore of considerable interest for mechanistic, structural and functional studies with these 
enzymes, and also as potential candidates for anti-infective drug discovery [5]. 
We have recently developed a new class of inhibitors and fluorescent probes for GTs by 
installing an additional substituent at the nucleobase of the sugar-nucleotide donor [6,7]. 
Examples for base-modified sugar-nucleotides, containing either non-natural 
sugar/nucleotide combinations [8] or additional substituents at the nucleobase [9], are still 
relatively rare. We have shown that 5-substituted derivatives of UDP-α-D-galactose are poor 
substrates, but potent inhibitors for galactosyltransferases [6]. The additional substituent at 
the nucleobase of these donor analogues interferes with crucial conformational changes 
during the GT catalytic cycle, resulting in the observed substrate/inhibitor switch [6]. To date, 
we have applied this design concept only to UDP-sugar-dependent GTs [6,7]. In this study, 
we describe, for the first time, the application of this general strategy to a GDP-sugar-
dependent enzyme, the ManT Kre2p. 
Kre2p is a retaining α-1,2-ManT from S. cerevisiae, which catalyses the transfer of α-D-
mannose from a GDP-Man donor to an α-mannoside acceptor [10]. Kre2p is involved in the 
biosynthesis of cell wall O- and N-glycoproteins in yeast, and a homologue of the Candida 
albicans enzyme Mnt1p [11], which is essential for the viability and virulence of this 
pathogenic fungus. 
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We have prepared four base-modified derivatives of the Kre2p donor GDP-Man, and 
evaluated their activity towards this enzyme. The design of our target molecules was 
inspired by our previous discovery that base-modified UDP-sugars with an additional, bulky 
substituent in position 5 are potent inhibitors, but poor substrates for UDP-sugar-dependent 
GTs [6,7], due to interference of the additional 5-substituent with conformational changes 
during the enzyme catalytic cycle. In direct analogy to the UDP-sugar series, we therefore 
wanted to specifically explore the effect of bulky, aromatic or heteroaromatic substituents in 
position 6 or 8 of the GDP-Man nucleobase on Kre2p activity (Fig. 1). We have found that in 
the case of Kre2p, these modifications do not abolish donor substrate activity, in contrast to 
our observations in the UDP-sugar series [6]. The presence of an additional substituent at 
position 6 or 8 of the donor does, however, redirect Kre2p activity from mannosyl transfer to 
hydrolysis. These results suggest that modification of the nucleobase is tolerated by this 
ManT, but that the functional consequences of this modification are different from those 
observed with base-modified UDP-sugars and UDP-sugar-dependent GTs. 
 
Figure 1 GDP-α-D-mannose (GDP-Man) and base-modified target molecules of the 
present study 
 
 
Results & discussion 
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Chemical synthesis 
Installation of an aromatic or heteroaromatic substituent at position 8 of GDP-Man was 
achieved via palladium-catalysed Suzuki-Miyaura cross-coupling chemistry. Thus, the 8-
substituted GDP-Man derivatives 2 and 3 (Fig. 1) were prepared from 8-bromo GDP-Man 1 
and the requisite phenyl- or furan-2-yl boronic acid as previously reported [12]. For the 
synthesis of 6-substituted NDP-mannose derivatives, we intended to use a similar cross-
coupling strategy. Ideally, we wanted to carry out the cross-coupling step at the stage of the 
sugar-nucleotide, to facilitate structural diversification. We therefore required a suitable 6-
halo nucleoside precursor, which could be readily elaborated into the corresponding NDP-
mannose derivative as the cross-coupling substrate. We chose 2-amino-6-chloro-purine 
riboside 6 as a suitable building block, as purine nucleosides with a chloro substituent at 
position 6 have been shown to readily undergo Suzuki-Miyaura cross-coupling reactions [13]. 
2-Amino-6-chloro-purine riboside 6 was prepared as depicted in Scheme 1. Peracetylated 
guanosine 4 was chlorinated using POCl3 in acetonitrile to give 2-amino-6-chloro-2',3',5'-tri-
O-acetyl purine riboside 5 in quantitative yield. Unfortunately, the chemical deprotection of 5 
under either acidic or basic conditions was unsuccessful. Thus, the use of acetyl chloride in 
methanol resulted in cleavage of the ribose bond, while the use of K2CO3 in methanol led to 
the substitution of the 6-chloro substituent with a methoxy group. Successful deprotection of 
5 was finally achieved enzymatically [14], using a commercially available lipase. With this 
method, the protecting groups were readily removed under mild, neutral conditions to give 6-
chloro-2-amino-purine riboside 6 in 55 % yield. 
Nucleoside 6 was converted into the corresponding mono- (7) and triphosphate (8) by 
selective phosphorylation at 5’-OH with POCl3 using Ikemoto’s protocol for the Yoshikawa 
reaction (Scheme 1) [15,16]. Previously, we found that the Yoshikawa phosphorylation of 8-
substituted guanosine derivatives can be complicated by acid-catalysed cleavage of the 
glycosidic bond, and therefore requires the presence of a base, e.g. proton sponge [17]. In 
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contrast, 2-amino-6-chloropurine riboside 6 proved to be less sensitive to acidic conditions 
and the phosphorylation could be performed under the original Yoshikawa-Ikemoto 
conditions, providing nucleoside monophosphate 7 in 54% yield. The corresponding 
triphosphate 8 was obtained in analogous fashion in 19% yield from 6, using Ludwig’s 
procedure [18], once again without the requirement for the use of proton sponge. 
Scheme 1 Synthesis of key intermediates 6-8a 
 
aReagents and conditions: (i) POCl3, benzyltriethylammonium chloride, dimethylaniline, 
MeCN, 90°C, 10 min; (ii) Novozyme, phosphate buffer (30 mM, pH 8.0), 60°C, 8 days; (iii) 
POCl3, triethylphosphate, H2O, 0°C; (iv) O(PO3)2(Bu3NH)4, DMF, 0°C; then TEAB (0.2M). 
 
With the mono- (7) and triphosphate (8) of 2-amino-6-chloro-purine riboside 6 in hand, we 
explored both an enzymatic and a chemical route towards the corresponding NDP-mannose 
derivative 9 (Scheme 2). The enzymatic synthesis of 9 from triphosphate 8 and mannose-1-
phosphate using GDP-mannose pyrophosphorylase was unsuccessful. The chemical 
synthesis of sugar-nucleotide 9 required the activation of nucleoside monophosphate 7 prior 
to pyrophosphate bond formation. Thus, 7 was converted into the corresponding 
phosphoromorpholidate via a dipyridyl disulfide/triphenylphosphine-mediated redox 
condensation with morpholine [19, 20]. The resulting phosphoromorpholidate was reacted 
successfully with mannose-1-phosphate under MnCl2 catalysis to form the pyrophosphate 
bond, as evidenced by the 31P NMR spectrum of the reaction product. 
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However, 1H NMR and mass spectroscopic analysis of the resulting sugar-nucleotide 
showed that during this reaction sequence, the chloro substituent in position 6 had 
unexpectedly been replaced with a morpholino group, resulting in the formation of NDP-
mannose derivative 10 instead of 9. This side reaction can be attributed to the pronounced 
susceptibility of the 6-position in 7 to nucleophilic attack. Such SNAr displacement reactions 
of 6-halopurines with amines have been employed e.g. for the preparation of N6-substituted 
adenosine derivatives [21]. Unfortunately, all efforts to suppress this chloro/morpholino 
exchange reaction during the pyrophosphate bond formation step remained unsuccessful. 
As our primary interest was to explore the tolerance of Kre2p towards additional, bulky 
substituents in position 6 of the sugar-nucleotide donor, we therefore decided at this stage to 
evaluate sugar-nucleotide 10 as a potential donor substrate of Kre2p. 
 
Scheme 2 Synthesis of 6-substituted NDP-mannose derivative 10a 
 
aReagents and conditions: (i) (a) morpholine, PPh3, dipyridyl disulfide, DMSO, rt; (b) 
mannose-1-phosphate, MnCl2, MgSO4, formamide, rt. 
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Biochemical evaluation 
Sugar-nucleotides 1-3 and 10 were tested as donor substrates for Kre2p, with 
methylmannoside as the acceptor substrate. To follow the enzymatic reactions, the 
consumption of the respective starting NDP-mannose was monitored by HPLC. Aliquots 
were removed from each reaction and analysed by RP-HPLC with UV detection. To account 
for non-specific as well as enzyme-catalysed hydrolysis, two control experiments were 
carried out in each assay: one in the absence of enzyme, and another in the absence of 
acceptor.  
First, the enzymatic conditions were optimized to achieve complete conversion of the natural 
donor substrate GDP-Man within 15 mins. In the absence of enzyme, no change in the GDP-
mannose peak was observed over 60 min, demonstrating the chemical stability of GDP-Man 
under the assay conditions. In the absence of acceptor, a decrease of GDP-Man was 
observed but at a much slower rate (<10% after 60 min) than in the presence of acceptor. 
The primary product of this slow, enzymatic hydrolysis of GDP-Man was GDP, indicating that 
hydrolysis occurred at the anomeric position of the donor. 
The time course of the enzymatic reactions with all four base-modified NDP-mannose 
derivatives is shown in Fig. 2. Table 1 shows the % conversion based on peak area for each 
of the analogues after maximum incubation time (4-48h). For all four compounds, no, or 
almost no, conversion was observed in the control experiment without enzyme (Fig. 2, Table 
1). This demonstrates that 1-3 and 10 are all chemically stable under the conditions of the 
enzyme assay. In the presence of both Kre2p and acceptor, all four donor analogues were 
turned over, albeit at different rates, and much more slowly than the natural donor GDP-Man. 
This suggests that all four NDP-mannose derivatives are recognised as donor substrates by 
Kre2p, but less well than the parent sugar-nucleotide GDP-Man. Moreover, for each of the 
donor analogues a similar conversion profile was observed in the presence and absence of 
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acceptor. This indicates that these base-modified analogues are used by Kre2p as donors 
not for glycosyl transfer, but for hydrolysis. 
Table 1 Conversion (%) of NDP-mannose derivatives 1-3 and 10 by the yeast 
mannosyltransferase Kre2p after maximum incubation time (4-48h). Data extracted from 
Figure 2. 
Cmpd Time (h) Conversion (%) 
+ acceptor 
+ enzyme 
- acceptor 
+ enzyme 
+ acceptor 
- enzyme 
1 30 91% 86% 8% 
2 48 78% 63% 0% 
3 48 71% 72% 0% 
10 4 63% 60% 9% 
 
Fig. 2 Donor substrate activity of NDP-mannose derivatives 1-3 and 10 towards the yeast 
mannosyltransferase Kre2p.a 
 
 
 
 
aConditions: donor analogue (0.1 mM), α-methyl-mannoside acceptor (4 mM), Kre2p (0.05 
mU/µL), Tris-HCl buffer (50 mM, pH 7.6), MnCl2 (10 mM), 37 oC, 4-48h. Each experiment 
was carried out in duplicate. 
 
A possible explanation for this behaviour is, that these base-modified NDP-Man derivatives 
are bound by Kre2p in a non-productive orientation, which allows the hydrolytic cleavage of 
A B 
C D 
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the mannose, but not its transfer to acceptor. This is in keeping with a recent theoretical 
study, which indicates that the Kre2p acceptor itself plays a crucial role in protecting the 
anomeric carbon of the donor against unwanted hydrolysis [22]. Very likely, the acceptor 
cannot perform this protective function if either the donor, or the acceptor, or both are not 
oriented correctly – as a result, for example, of the donor base modification. In this case, 
enzymatic donor hydrolysis will occur both in the presence and absence of acceptor, as 
observed for all four base-modified NDP-Man derivatives. 
Interestingly, the 8-substituted derivatives showed a much slower turnover rate (30-48h) 
than the 6-substituted derivative (4h), suggesting that additional substitutents in the 6-
position are better tolerated by the enzyme than substituents in the 8-position. This could be 
due to the difference in conformation between the 6- and 8-substituted analogues. The 
crystal structure of Kre2p in complex with GDP shows this nucleotide bound at the 
nucleotide binding pocket in the anti conformation (Fig. 3), stabilised by hydrogen bonds 
between Kre2p and N-1 and N-2 of the guanine base [10]. It is well known that in solution, 
guanosine analogues with bulky substituents in the 8-position adopt preferentially the syn 
conformation. Binding of the 8-substituted GDP-Man derivatives 1-3 therefore requires a 
conformational change from the syn to the anti conformation, which may contribute to the 
prolonged time course we observed for these donor analogues. In contrast, the 6-substituted 
NDP-mannose 10 adopts the anti conformation already in solution. This facilitates its binding 
at Kre2p and may explain the considerably shorter time course compared to 1-3. 
Fig. 3 Syn and anti conformation of guanosine 
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Conclusion 
Four base-modified derivatives of GDP-Man have been prepared and tested as donor 
substrates for the yeast α-1,2-mannosyltransferase Kre2p. Our results suggest that an 
additional substituent at either the 6- or 8-position of the donor nucleobase is, in principle, 
tolerated by this enzyme. The additional substituent does, however, alter both the outcome 
and the time course of the enzymatic reaction: the presence of the additional substituent 
redirects the outcome of the Kre2p reaction from glycosyl transfer to hydrolysis. Moreover, 
all four donor analogues are turned over much more slowly than the natural donor GDP-Man. 
Contributing factors to the observed rank order of turnover rates (8-phenyl, 8-furanyl < 8-
bromo < 6-morpholinyl << GDP-Man) may be the steric bulk of the additional substituent, but 
also the different conformational preferences between the 8- and 6-substituted derivatives. 
Taken together, our results suggest that modification of the donor nucleobase is, in principle, 
a viable strategy for probe and inhibitor development against GDP-Man-dependent GTs. 
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Experimental section 
General 
All chemicals were obtained commercially and used as received unless stated otherwise.  
MeCN was dried (sodium) and stored over activated 4 Å molecular sieves.  TLC was 
performed on precoated aluminium plates (Silica Gel 60 F254, Merck).  Compounds were 
visualized by exposure to UV light.  NMR spectra were recorded at 298 K on a Varian VXR 
400 S spectrometer at 400 MHz (1H) or on a Bruker Avance DPX-300 spectrometer at 300 
MHz (1H).  Chemical shifts (δ) are reported in ppm and either referenced to residual solvent 
or to acetone (1H δ 2.05, 13C δ 30.83 for solutions in D2O).  Coupling constants (J) are 
reported in Hz.  Resonance allocations were made with the aid of COSY experiments.  
Accurate electrospray ionisation mass spectra (HR ESI-MS) were obtained on a Finnigan 
MAT 900 XLT mass spectrometer at the EPSRC National Mass Spectrometry Facilty, 
Swansea.  Analytical chromatography (HPLC) was carried out on an Agilent 1200 machine 
or a Perkin Elmer Series 200 machine equipped with a Supelcosil LC-18T column (25 cm × 
4.6 mm, particle size 5 µm) and a UV detector.  Preparative column chromatography was 
performed on silica gel 60 (particle size 0.063-0.2 mm).  Ion-pair and reversed phase 
chromatography were performed on a Bio-Rad BioLogic LP system.  TEAB 
(triethylammonium bicarbonate) buffer was prepared by bubbling CO2 gas through a mixture 
of Et3N in water until saturation was achieved. 
Purification method 1. Ion-pair chromatography was performed using Lichroprep RP-18 
resin, gradient 0-15% MeCN against TEAB (0.05M) over 400 mL, at a flow rate of 3 mL/min.  
Product-containing fractions were combined and reduced to dryness.  The residue was co-
evaporated with methanol to remove residual TEAB. 
Purification method 2. Anion exchange chromatography was performed using MacroPrep 
25Q resin, gradient 0-100% TEAB (1M, pH 7.3) against H2O over 400 mL, then 100% TEAB 
(1M, pH 7.3) over 80 mL, at a flow rate of 3 mL/min.  Product-containing fractions were 
combined and reduced to dryness.  The residue was co-evaporated with methanol to 
remove residual TEAB. 
8-Bromo GDP-mannose 1, 8-phenyl GDP-mannose 2, and 8-(2-furanyl) GDP mannose 3 
were prepared as previously described [12]. 
2-Amino-6-chloro-2',3',5'-tri-O-acetyl purine riboside (5). 
In an oven-dried flask, peracetylated guanosine 4 [23] (1.56 g, 3.81 mmol), 
benzyltriethylammonium chloride (1.74 g, 7.64 mmol) and N,N-dimethylaniline (530 µL, 4.18 
mmol) were dissolved in dry MeCN (15 mL).  POCl3 (1.8 mL, 19.3 mmol) was added and the 
reaction immersed in a pre-heated oil bath at 90oC for 10 min.  All volatiles were flash-
evaporated and the blue residue dissolved in chloroform and stirred with crushed ice for 15 
min.  The organic phase was washed with water (3 x 5 mL), and 5% aq. NaHCO3 solution (3 
x 10 mL), and dried over MgSO4.  All solvents were removed in vacuo to give 5 as an oil in 
quantitative yield, which was used in the next step without further purification.  1H NMR (400 
MHz, DMSO-d6): δ 7.87 (s, 1H, H-8), 6.01 (d, J = 4.93 Hz, 1H, H-1'), 5.95 (t, J = 5.07, 5.07 
Hz, 1H, H-2'), 5.74 (t, J = 4.97, 4.97 Hz, 1H, H-3'), 5.20 (s, 2H, NH2), 4.42 (m, 3H, H-4', H2-
5'), 2.15 (s, 3H, OAc), 2.10 (s, 3H, OAc), 2.09 (s, 3H, OAc);  13C NMR (100 MHz, DMSO-d6) 
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ppm 170.5, 169.6, 169.3, 159.1, 153.0, 151.9, 140.7, 125.8, 86.6, 80.0, 72.7, 70.4, 62.9, 
20.7, 20.5, 20.4. 
2-Amino-6-chloropurine riboside (6). 
Novozyme (1.6 g) in phosphate buffer (58 mL, pH 8) was added to a solution of 5 (1.56 g, 
3.64 mmol) in acetone (10 mL).  The mixture was stirred at 60oC for 8 days.  The enzyme 
was removed by filtration and washed with ethanol (50 mL) and acetone (50 mL).  The 
filtrate was evaporated in vacuo and the crude residue purified by column chromatography 
(SiO2, CH2Cl2:MeOH, 85:15) to yield 0.61 g (55%) of 6 as a pale blue powder.  1H NMR (400 
MHz, DMSO-d6): δ  8.38 (s, 1H, H-8), 6.99 (s, 1H, NH2), 5.81 (d, J = 5.80 Hz, 1H, H-1'), 5.49 
(br s, 1H, OH-2'), 5.19 (br s, 1H, OH-3'), 5.05 (t, J = 5.24, 5.24 Hz, 1H, OH-5'), 4.47 (t, J = 
4.85, 4.85 Hz, 1H, H-2'), 4.20-4.02 (m, 1H, H-3'), 3.90 (q, J = 3.98, 3.95, 3.95 Hz, 1H, H-4'), 
3.69-3.60 (m, 1H, H2-5'), 3.59-3.52 (m, 1H, H2-5');  13C NMR (100 MHz, DMSO-d6) δ 160.5, 
154.7, 150.2, 141.9, 124.2, 87.4, 86.0, 74.2, 70.9, 61.9; High-resolution ES-MS m/z 
302.0649 ([M + H]+, C10H1335ClN5O4 calcd 302.0651). 
2-Amino-6-chloropurine riboside monophosphate (7). 
2-Amino-6-chloropurine riboside 6 (220 mg, 0.745 mmol) was dissolved in triethylphosphate 
(2 mL) by gentle heating. H2O (6.7 µL, 0.37 mmol) was added and the solution cooled to 0oC 
in an ice-salt bath.  POCl3 (280 µL, 3.00 mmol) was added dropwise and the solution stirred 
at 2-4oC for 1 hr.  The reaction was quenched by stirring with crushed ice for 15 min.  The 
pH was adjusted to 7 with 2M NaOH, the aqueous phase washed with EtOAc (3 x 30 mL) 
and all solvents removed in vacuo.  The residue was purified by method 1 to remove excess 
salts, then by method 2 (fractions 44-60) to yield 220 mg of 7 (54%, 1.6 equiv. 
triethylammonium as determined by NMR).  1H NMR (400 MHz, D2O): δ 8.23 (s, 1H, H-8), 
5.78 (d, 1H, J = 5.1 Hz, H-1'), 4.59 (t, J = 5.1, 5.1 Hz, 1H, H-2'), 4.35-4.33 (m, 1H, H-3'), 4.18 
(m, 1H, H-4'), 3.98 – 3.90 (m, 2H, H2-5'), 3.00 (q, J = 7.1, 7.3, 7.3 Hz, 9.5H, CH2), 1.08 (t, J = 
7.1, 7.3 Hz, 14.5H, CH3);  13C NMR (100 MHz, D2O) δ 159.8, 153.6, 150.7, 142.6, 124.0, 
87.9, 84.6 (d, Jc,p = 9.1 Hz), 74.6, 71.0, 64.6, 47.1, 8.8.   31P NMR (162 MHz, D2O): δ 7.31;  
High-resolution ES-MS m/z 380.0163 (monoanion, C10H1235ClN5O7P calcd 380.0168). 
2-Amino-6-chloropurine riboside triphosphate (8). 
2-Amino-6-chloropurine riboside 6 (100.5 mg, 0.33 mmol) was dissolved in triethylphosphate 
(2.5 mL) by gentle heating, H2O (3 µL, 0.167 mmol) was added and the solution cooled to 
0oC in an ice-salt bath.  POCl3 (124 µL, 1.32 mmol) was added dropwise and the solution 
stirred at 2-4oC for 3 hr.  A cold mixture of Bu3N (330 µL, 1.39 mmol) and tributylammonium 
pyrophosphate (2.33 mmol) in DMF (2.5 mL) was added in one portion and the reaction 
stirred at 4oC for 30 min.  The reaction was quenched by stirring with ice cold TEAB (0.2M) 
for 15 min.  The reaction was washed with EtOAc (3 x 30 mL) and all solvents removed in 
vacuo.  The residue was purified by method 1 to remove excess salts, then by method 2 
(fractions 18-24) to yield 54.1 mg of 8 (19%, 3 equiv. triethylammonium as determined by 
NMR).  1H NMR (400 MHz, D2O) δ 8.29 (s, 1H, H-8), 5.85 (d, J = 5.7 Hz, 1H, H-1'), 4.44 (br s, 
1H, H-3'), 4.21 (br s, 1H, H-4'), 4.08 (m, 2H, and H2-5'), 3.01 (q, J = 7.3 Hz, 25H, CH2), 1.09 
(t, J = 7.3 Hz, 38H, CH3);  13C NMR (100 MHz, D2O): δ 159.4, 153.2, 150.3, 142.0, 123.7, 
86.7, 83.7 (d, Jc,p = 8.0 Hz), 73.3, 70.0, 64.9, 46.3, 7.9;  31P NMR (121 MHz, D2O): δ -4.04 (d, 
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J = 20.6 Hz), -9.01 (d, J = 19.4 Hz), -20.16 (t, J = 20.6, 19.4 Hz);  High-resolution ES-MS 
m/z 539.9491 (monoanion, C10H14N5O1335Cl P3 calcd 539.9495). 
2-Amino-6-morpholinylpurine riboside diphosphate mannose (10). 
Nucleoside monophosphate 7 (125 mg, 0.231 mmol) was dissolved in dry DMSO (0.5 mL) 
and co-evaporated with dry DMF (3 x 2 mL). Morpholine was added (121 µL, 1.39 mmol) 
and the reaction stirred at rt for 5 min.  Dipyridyl disulfide (154 mg, 0.70 mmol) was added 
and stirring continued for 5 min.  Finely ground triphenylphosphine (177 mg, 0.67 mmol) was 
added and stirring continued for 3 hr.  0.1 M NaI solution in acetone was added dropwise 
until precipitation was complete.  The white precipitate formed was collected by filtration and 
washed with acetone.  The crude morpholidate was used in the next step without further 
purification.  The morpholidate and mannose-1-phosphate (70 mg, 0.162 mmol) were 
dissolved in dry pyridine (5 mL) and evaporated to dryness several times.  MgSO4 (36 mg, 
0.30 mmol) and dry 0.2 M MnCl2 in formamide (1.1 mL) were added and the solution stirred 
at rt under N2 for 6 days.  MeCN was added dropwise until precipitation was complete and 
the supernatant was removed.  The red oily residue was purified by method 1 followed by 
method 2.  The thin film obtained was dissolved in H2O (5 mL) and treated with Chelex 100 
resin Na+ form.  The resin was filtered off and washed with water and the filtrate reduced to 
dryness to yield 24.5 mg (14%) of 10 as a glassy solid.  1H NMR (400 MHz, D2O): δ 7.93 (s, 
1H, H-8), 5.76 (d, J = 6.4 Hz, 1H, H-1'), 5.29 (d, J = 8.0 Hz, 1H, H-1''), 4.52 (m, 2H, H-2', H-
3'), 4.28 (m, 1H, H-4'), 4.14 (m, 1H, H-5'a), 3.98 (m, 1H, H-5'b), 3.89 (br s, 4H, 2 x CH2), 3.83 
(m, 1H, H-2''), 3.75 (m, 1H, H-3''), 3.69 (d, J = 9.6, 3.2 Hz, 1H, H-4''), 3.53 (m, 7H, H-6'', H-5'', 
2 x CH2);  31P NMR (121 MHz, D2O): δ -7.89 (d, J = 20.3 Hz), -10.17 (d, J = 20.2 Hz); High-
resolution ES-MS m/z 673.1272 (monoanion, C20H31N6O16P2 calcd 673.1277). 
Biochemical assays. 
Analytical chromatography 
Analytical chromatography (HPLC) was carried out on an Agilent 1200 machine or a Perkin 
Elmer Series 200 machine equipped with a Supelcosil LC-18T column (25cm ×4.6mm, 
particle size 5 µm) and a UV detector.  Methanol used was HPLC grade.  0.05 M TEA-
phosphate buffer (1L) was prepared by mixing TEA (12.4 mL) and H3PO4 (6.2 mL) in MilliQ 
water, adjusting the pH to 7.0 with TEA and passing through a 0.45 m filter.  Injection 
volume 20 L.  HPLC conditions used for each substrate were as follows: 8-bromo-GDP-
mannose (1): isocratic 10% MeOH against 0.05 M TEA-Phosphate buffer (pH 7.0), run time 
25 min, detection at 262 nm. 8-Phenyl and 8-furanyl GDP-mannose (2 & 3): gradient of 15-
30% MeOH against TEA-Phosphate buffer (0.05M, pH 7.0), run time 15 min, detection at 
280 nm. 2-Amino-6-morpholinylpurine riboside diphosphate mannose (10): isocratic 15% 
MeOH against TEA-Phosphate buffer (0.05M, pH 7.0), run time 30 min, detection at 254 nm.  
Enzyme assay 
Recombinant Kre2p was purchased from Sigma. Donor (GDP-mannose) or donor analogue 
(1-3, 10, 0.1 mM), α-methyl-mannoside acceptor (4 mM) and Kre2p (0.05 mU/µL) in a total 
volume of 200 µL of Tris-HCl buffer (50 mM, pH 7.6) containing MnCl2 (10 mM) were 
incubated at 37 oC for the required time (4-48h).  Aliquots of 20 µL were taken at regular 
intervals, diluted to 40 µL and kept at 0 oC to quench the reaction, prior to analysis by RP-
HPLC. The residual amount of donor or donor analogue at each time point was determined 
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by HPLC and calculated (in %) relative to the corresponding amount at t = 0. Control 
experiments contained buffer instead of acceptor or enzyme. Each assay was carried out in 
duplicate. 
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Highlights 
 
(1) GDP-mannose derivatives with an additional substituent in position 6 or 8 of the 
nucleobase are recognised as donor substrates by the S. cerevisiae α-1,2-
mannosyltransferase Kre2p 
(2) The additional substituent redirects donor substrate activity from glycosyl transfer to 
donor hydrolysis 
(3) Position and steric bulk of the additional substituent, as well as conformational 
preferences, are determining factors for the observed activities 
 
